1. Park BJ. Prospectus of the Korean Society for Pharmacoepidemiology and Risk Management. J Pharmacoepidemiol Risk Manag 2008;1:5-7.
2. Korea Food and Drug Administration. Pharmacovigilance Research Network. Standard operation procedures for pharmacovigilance research network regional pharmacovigilance centers 2011;Seoul: Pharmacovigilance Research Network.
3. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health 2007;40:278-284.
4. Jang BW. Pharmaceutical affairs law and administration 2012;Seoul: SinilBooks. 520.
5. Uppsala Monitoring Center. Active ICSRS in the WHO global ICSR database per million inhabitants and year [Internet] 2012;cited 2012 Aug 27. Uppsala: Uppsala Monitoring Center. Available from:
http://who-umc.org/graphics/26930.gif
7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-486.
8. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004;13:519-523.
9. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998;54:315-321.
10. Seong JM, Choi NK, Ahn SH, Park BJ. Development of signal detection program for adverse drug reaction. J Pharmacoepidemiol Risk Manag 2011;4:15-21.
11. Council for International Organizations of Medical Sciences Working Group VIII. Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII 2010;Geneva: Council for International Organizations of Medical Sciences.
12. Stahl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004;13:355-363.
13. Center for Drug Evaluation and Research (US). Center for Biologics Evaluation and Research (US). Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment 2005;Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research.
14. Waller PC, Tilson HH. In: Stephens MD, Talbot JC, Waller P, editor. Managing drug safety issues with marketed products. Stephens' detection of new adverse drug reactions 2004;5th ed. Hoboken: John Wiley & Sons. 345-374.
15. Loke YK, Price D, Herxheimer A. Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Med Res Methodol 2007;7:32.
16. Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Casale RL. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2012;21:1-10.
17. Choi NK, Hahn S, Park BJ. Increase in mortality rate following coprescription of cisapride and contraindicated drugs. Ann Pharmacother 2007;41:667-673.
18. Park BJ. Drug utilization review. J Pharmacoepidemiol Risk Manag 2008;1:13-19.
19. Choi NK, Park BJ. Strategy for establishing an effective Korean drug utilization review system. J Korean Med Assoc 2010;53:1130-1138.